Does Rallies show Form 4 insider transactions for SLNO?

Yes. Rallies tracks SLNO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is SLNO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SLNO. It does not provide personalized investment advice.

SLNO (Soleno Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Soleno Therapeutics, Inc. Common Stock (SLNO) is a publicly traded Healthcare sector company. As of May 21, 2026, SLNO trades at $53.01 with a market cap of $2.76B and a P/E ratio of 132.53. SLNO moved +0.01% today. Year to date, SLNO is +14.52%; over the trailing twelve months it is -29.39%. Its 52-week range spans $29.43 to $90.32. Analyst consensus is neutral with an average price target of $61.00. Rallies surfaces SLNO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading SLNO stock inside the company?

Recent SLNO insider activity includes Manning Meredith sold 4.86K, Manning Meredith sold 2.10K, Manning Meredith sold 558, Huang Michael F. sold 4.26K, and Huang Michael F. sold 1.84K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

SLNO Key Metrics

Key financial metrics for SLNO
Metric	Value
Price	$53.01
Market Cap	$2.76B
P/E Ratio	132.53
EPS	$0.40
Dividend Yield	0.00%
52-Week High	$90.32
52-Week Low	$29.43
Volume	0
Avg Volume	0
Revenue (TTM)	$190.41M
Net Income	$20.89M
Gross Margin	98.58%

Recent SLNO Insider Trades

Manning Meredith sold 4.86K (~$146.10K) on Mar 27, 2026.
Manning Meredith sold 2.10K (~$65.18K) on Mar 27, 2026.
Manning Meredith sold 558 (~$17.70K) on Mar 27, 2026.
Huang Michael F. sold 4.26K (~$127.84K) on Mar 27, 2026.
Huang Michael F. sold 1.84K (~$57.05K) on Mar 27, 2026.

Latest SLNO News

Halper Sadeh Targets Soleno Therapeutics $53 Per Share Sale to Neurocrine — Apr 23, 2026
Neurocrine to Acquire Soleno Therapeutics for $2.9B at 34% Premium — Apr 12, 2026
Soleno Therapeutics' $53/share Sale to Neurocrine Sparks Fiduciary Probe — Apr 10, 2026
Neurocrine to Acquire Soleno for $53 per Share, 34% Premium — Apr 6, 2026
Soleno Therapeutics' Price Targets Slashed to $110 and $85 After Q4 Surge — Mar 1, 2026

SLNO Analyst Consensus

12 analysts cover SLNO: 0 strong buy, 1 buy, 11 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $61.00.

Common questions about SLNO

Who is trading SLNO stock inside the company?: Recent SLNO insider activity includes Manning Meredith sold 4.86K, Manning Meredith sold 2.10K, Manning Meredith sold 558, Huang Michael F. sold 4.26K, and Huang Michael F. sold 1.84K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for SLNO?: Yes. Rallies tracks SLNO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is SLNO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SLNO. It does not provide personalized investment advice.